期刊
FUTURE ONCOLOGY
卷 11, 期 17, 页码 2471-2484出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.15.118
关键词
ipilimumab; nivolumab; pruritus; rash; vitiligo
类别
Background: We performed a meta-analysis of the risk of cutaneous toxicities associated with immune checkpoint inhibitors. Methods: Eligible studies included randomized trials of patients with solid tumors on immune checkpoint inhibitors (ipilimumab, nivolumab, tremelimumab, pidlizumab and pembrolizumab); describing events of rash, vitiligo and pruritus. Results: A total of nine clinical trials were considered eligible for the meta-analysis. The relative risk of all-grade rash, vitiligo and pruritus was 4.06 (95% CI: 3.35-4.91; p < 0.0001), 16.3 (95% CI: 3.21-82.8; p = 0.0008) and 3.4 (95% CI: 2.24-5.16; p < 0.00001), respectively. Conclusion: Our meta-analysis demonstrates that immune checkpoint inhibitors are associated with an increased risk of all grade skin rash, vitiligo and pruritus. Clinicians should perform regular clinical cutaneous monitoring.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据